Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study (Q50546113)

15 March 2018

title

Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study (English)

1 reference

15 March 2018

author

Antony Payton

3

1 reference

15 March 2018

Simon Anderson

5

1 reference

15 March 2018

Alison R. Yung

object named as

Alison Yung

8

0 references

author name string

Adrian H Heald

1

1 reference

15 March 2018

Julie L Martin

2

1 reference

15 March 2018

Luma Khalid

4

1 reference

15 March 2018

R Prakash Narayanan

6

1 reference

15 March 2018

Marc De Hert

7

1 reference

15 March 2018

Mark Livingston

9

1 reference

15 March 2018

publication date

14 January 2016

1 reference

15 March 2018

Australian and New Zealand Journal of Psychiatry

published in

1 reference

15 March 2018

volume

51

1 reference

15 March 2018

issue

1

1 reference

15 March 2018

page(s)

75-82

1 reference

15 March 2018

Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean?

cites work

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Weight gain. A side-effect of tricyclic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

The prevalence of metabolic syndrome amongst patients with severe mental illness in the community in Hong Kong--a cross sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Excess mortality of schizophrenia. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

A behavioral weight-loss intervention in persons with serious mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Creating medical and drug code lists to identify cases in primary care databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Obesity, serious mental illness and antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Common mental disorder and obesity: insight from four repeat measures over 19 years: prospective Whitehall II cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Dietary improvement in people with schizophrenia: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Standard cardiovascular disease risk algorithms underestimate the risk of cardiovascular disease in schizophrenia: evidence from a national primary care database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Statins for primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Physical health monitoring of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Screening for metabolic risk among patients with severe mental illness and diabetes: a national comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0004867415625817

21 January 2018

Identifiers

DOI

10.1177/0004867415625817

1 reference

15 March 2018

1 reference

15 March 2018